Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' LENNARD MS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 38 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Hayhurst, GP; Harlow, J; Chowdry, J; Gross, E; Hilton, E; Lennard, MS; Tucker, GT; Ellis, SW
      Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6

      BIOCHEMICAL JOURNAL
    2. Stachulski, AV; Lennard, MS
      Drug metabolism: The body's defense against chemical attack (vol 77, pg 349, 2000)

      JOURNAL OF CHEMICAL EDUCATION
    3. Forsyth, JT; Grunewald, RA; Rostami-Hodjegan, A; Lennard, MS; Sagar, HJ; Tucker, GT
      Parkinson's disease and CYP1A2 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Ellis, SW; Hayhurst, GP; Lightfoot, T; Smith, G; Harlow, J; Rowland-Yeo, K; Larsson, C; Mahling, J; Lim, CK; Wolf, CR; Blackburn, MG; Lennard, MS; Tucker, GT
      Evidence that serine 304 is not a key ligand-binding residue in the activesite of cytochrome P450 2D6

      BIOCHEMICAL JOURNAL
    5. Coleman, T; Spellman, EF; Rostami-Hodjegan, A; Lennard, MS; Tucker, GT
      The 1 '-hydroxylation of rac-bufuralol by rat brain microsomes

      DRUG METABOLISM AND DISPOSITION
    6. Lightfoot, T; Ellis, SW; Mahling, J; Ackland, MJ; Blaney, FE; Bijloo, GJ; De Groot, MJ; Vermeulen, NPE; Blackburn, GM; Lennard, MS; Tucker, GT
      Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling

      XENOBIOTICA
    7. Stachulski, AV; Lennard, MS
      Drug metabolism: The body's defense against chemical attack

      JOURNAL OF CHEMICAL EDUCATION
    8. Manap, RA; Wright, CE; Gregory, A; Rostami-Hodjegan, A; Meller, ST; Kelm, GR; Lennard, MS; Tucker, GT; Morice, AH
      The antitussive effect of dextromethorphan in relation to CYP2D6 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    9. Forsyth, J; Grunewald, RA; Lennard, MS; Rostami-Hodjegan, A; Sagar, HJ; Tucker, GT
      Altered caffeine metabolism in patients with Parkinson's disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    10. Abdul-Manap, R; Wright, CE; Rostami-Hodjegan, A; Meller, S; Lennard, MS; Morice, AH; Tucker, GT
      Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    11. Rostami-Hodjegan, A; Forsyth, J; Grunewald, RA; Lennard, MS; Sagar, HJ; Tucker, GT
      The paraxanthine caffeine ratio in saliva as a marker of CYP1A2 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. ROSTAMIHODJEGAN A; LENNARD MS; WOODS HE; TUCKER GT
      METAANALYSIS OF STUDIES OF THE CYP2D6 POLYMORPHISM IN RELATION TO LUNG-CANCER AND PARKINSONS-DISEASE

      Pharmacogenetics
    13. SIMOOYA OO; SIJUMBILA G; LENNARD MS; TUCKER GT
      HALOFANTRINE AND CHLOROQUINE INHIBIT CYP2D6 ACTIVITY IN HEALTHY ZAMBIANS (VOL 45, PG 315, 1998)

      British journal of clinical pharmacology
    14. SIMOOYA OO; SIJUMBIL G; LENNARD MS; TUCKER GT
      HALOFANTRINE AND CHLOROQUINE INHIBIT CYP2D6 ACTIVITY IN HEALTHY ZAMBIANS

      British journal of clinical pharmacology
    15. GHAHRAMANI P; ELLIS SW; LENNARD MS; RAMSAY LE; TUCKER GT
      CYTOCHROMES P450 MEDIATING THE N-DEMETHYLATION OF AMITRIPTYLINE

      British journal of clinical pharmacology
    16. LIN LY; DISTEFANO EW; SCHMITZ DA; HSU L; ELLIS SW; LENNARD MS; TUCKER GT; CHO AK
      OXIDATION OF METHAMPHETAMINE AND METHYLENEDIOXYMETHAMPHETAMINE BY CYP2D6

      Drug metabolism and disposition
    17. LENNARD MS; CREWE HK; ELLIS SW; TUCKER GT
      THE 4-HYDROXYLATION OF TAMOXIFEN BY HUMAN LIVER CYTOCHROMES P450 2D6,2C9 AND 3A4

      Clinical pharmacology and therapeutics
    18. CREWE HK; ELLIS SW; LENNARD MS; TUCKER GT
      VARIABLE CONTRIBUTION OF CYTOCHROMES P450 2D6, 2C9 AND 3A4 TO THE 4-HYDROXYLATION OF TAMOXIFEN BY HUMAN LIVER-MICROSOMES

      Biochemical pharmacology
    19. GHAHRAMANI P; LENNARD MS
      QUANTITATIVE-ANALYSIS OF AMITRIPTYLINE AND NORTRIPTYLINE IN HUMAN PLASMA AND LIVER MICROSOMAL PREPARATIONS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical applications
    20. JENNINGS M; SWEETLAND H; SMITH CAD; WOLF CR; LENNARD MS; TUCKER GT; WOODS HF; ROGERS K
      LACK OF RELATIONSHIPS BETWEEN THE DEBRISOQUINE (CYP2D6) AND MEPHENYTION (CYP2C19) OXIDATION POLYMORPHISMS AND SUSCEPTIBILITY TO BREAST-CANCER

      Breast
    21. ROWLAND K; ELLIS SW; LENNARD MS; TUCKER GT
      VARIABLE CONTRIBUTION OF CYP2D6 TO THE N-DEALKYLATION OF S-(-)-PROPRANOLOL BY HUMAN LIVER-MICROSOMES

      British journal of clinical pharmacology
    22. ELLIS SW; ROWLAND K; ACKLAND MJ; REKKA E; SIMULA AP; LENNARD MS; WOLF CR; TUCKER GT
      INFLUENCE OF AMINO-ACID RESIDUE-374 OF CYTOCHROME-P-450 2D6 (CYP2D6) ON THE REGIO-SELECTIVE AND ENANTIO-SELECTIVE METABOLISM OF METOPROLOL

      Biochemical journal
    23. COLEMAN T; ELLIS SW; MARTIN IJ; LENNARD MS; TUCKER GT
      1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IS N-DEMETHYLATEDBY CYTOCHROMES P450 2D6, 1A2 AND 3A4 - IMPLICATIONS FOR SUSCEPTIBILITY TO PARKINSONS-DISEASE

      The Journal of pharmacology and experimental therapeutics
    24. COE PL; LENNARD MS; TATLOW JC
      CHLOROPOLYFLUORODIETHYL ETHERS

      Journal of fluorine chemistry
    25. COLEMAN T; ELLIS SW; MARTIN IJ; LENNARD MS; TUCKER GT
      MPTP IS N-DEMETHYLATED BY CYPS 2D6, 1A2 AND 3A4 - IMPLICATIONS FOR SUSCEPTIBILITY TO PARKINSONS-DISEASE

      British Journal of Pharmacology
    26. GARDNER IB; WALKER DK; LENNARD MS; SMITH DA; TUCKER GT
      COMPARISON OF THE DISPOSITION OF 2 NOVEL COMBINED THROMBOXANE SYNTHASE INHIBITORS THROMBAXANE-A(2) RECEPTOR ANTAGONISTS IN THE ISOLATED-PERFUSED RAT-LIVER

      Xenobiotica
    27. ELLIS SW; HAYHURST GP; SMITH G; LIGHTFOOT T; WONG MMS; SIMULA AP; ACKLAND MJ; STERNBERG MJE; LENNARD MS; TUCKER GT; WOLF CR
      EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6

      The Journal of biological chemistry
    28. CHING MS; BLAKE CL; GHABRIAL H; ELLIS SW; LENNARD MS; TUCKER GT; SMALLWOOD RA
      POTENT INHIBITION OF YEAST-EXPRESSED CYP2D6 BY DIHYDROQUINIDINE, QUINIDINE, AND ITS METABOLITES

      Biochemical pharmacology
    29. BULSARA D; ACKLAND MJ; DUNCAN JN; REES SA; ELLIS SW; LENNARD MS; TUCKER GT
      EVALUATION OF A TEMPLATE MODEL OF THE CYP2D6 ACTIVE-SITE BY EXPERIMENTAL TESTING OF COMPOUNDS WITH RECOMBINANT HUMAN CYP2D6

      The FASEB journal
    30. WEERASURIYA K; JAYAKODY RL; SMITH CAD; WOLF CR; TUCKER GT; LENNARD MS
      DEBRISOQUINE AND MEPHENYTOIN OXIDATION IN SINHALESE - A POPULATION STUDY

      British journal of clinical pharmacology
    31. ROWLAND K; YEO WW; ELLIS SW; CHADWICK IG; HAQ I; LENNARD MS; JACKSON PR; RAMSAY LE; TUCKER GT
      INHIBITION OF CYP2D6 ACTIVITY BY TREATMENT WITH PROPRANOLOL AND THE ROLE OF 4-HYDROXY PROPRANOLOL

      British journal of clinical pharmacology
    32. WILLIAMS ML; LENNARD MS; MARTIN IJ; TUCKER GT
      INTERINDIVIDUAL VARIATION IN THE ISOMERIZATION OF 4-HYDROXYTAMOXIFEN BY HUMAN LIVER-MICROSOMES - INVOLVEMENT OF CYTOCHROMES P450

      Carcinogenesis
    33. ELLIS SW; ROWLAND K; HARLOW JR; SIMULA AP; LENNARD MS; WOODS HF; TUCKER GT; WOLF CR
      REGIOSELECTIVE AND ENANTIOSELECTIVE METABOLISM OF METOPROLOL BY 2 HUMAN CDNA-DERIVED CYP2D6 PROTEINS

      British Journal of Pharmacology
    34. BARHAM HM; LENNARD MS; TUCKER GT
      AN EVALUATION OF CYTOCHROME-P450 ISOFORM ACTIVITIES IN THE FEMALE DARK AGOUTI (DA) RAT - RELEVANCE TO ITS USE AS A MODEL OF THE CYP2D6 POORMETABOLIZER PHENOTYPE

      Biochemical pharmacology
    35. TUCKER GT; LENNARD MS; ELLIS SW; WOODS HF; CHO AK; LIN LY; HIRATSUKA A; SCHMITZ DA; CHU TYY
      THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)

      Biochemical pharmacology
    36. WATTS AR; LENNARD MS; MASON SL; TUCKER GT; WOODS HF
      BEETURIA AND THE BIOLOGICAL FATE OF BEETROOT PIGMENTS

      Pharmacogenetics
    37. SIMOOYA OO; NJUNJU E; HODJEGAN AR; LENNARD MS; TUCKER GT
      DEBRISOQUINE AND METOPROLOL OXIDATION IN ZAMBIANS - A POPULATION STUDY

      Pharmacogenetics
    38. LENNARD MS
      GENETICALLY-DETERMINED ADVERSE DRUG-REACTIONS INVOLVING METABOLISM

      Drug safety


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 18:33:05